209 related articles for article (PubMed ID: 35106936)
41. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
Staiger AM; Ziepert M; Horn H; Scott DW; Barth TFE; Bernd HW; Feller AC; Klapper W; Szczepanowski M; Hummel M; Stein H; Lenze D; Hansmann ML; Hartmann S; Möller P; Cogliatti S; Lenz G; Trümper L; Löffler M; Schmitz N; Pfreundschuh M; Rosenwald A; Ott G;
J Clin Oncol; 2017 Aug; 35(22):2515-2526. PubMed ID: 28525305
[TBL] [Abstract][Full Text] [Related]
42. Germinal center B (GCB) and non-GCB cell-like diffuse large B cell lymphomas have similar outcomes following autologous haematopoietic stem cell transplantation.
Costa LJ; Feldman AL; Micallef IN; Inwards DJ; Johnston PB; Porrata LF; Ansell SM
Br J Haematol; 2008 Jul; 142(3):404-12. PubMed ID: 18492096
[TBL] [Abstract][Full Text] [Related]
43. A super-SILAC based proteomics analysis of diffuse large B-cell lymphoma-NOS patient samples to identify new proteins that discriminate GCB and non-GCB lymphomas.
van der Meeren LE; Kluiver J; Rutgers B; Alsagoor Y; Kluin PM; van den Berg A; Visser L
PLoS One; 2019; 14(10):e0223260. PubMed ID: 31603917
[TBL] [Abstract][Full Text] [Related]
44. Evaluation of BCL-6, CD10, CD138 and MUM-1 expression in diffuse large B-cell lymphoma patients: CD138 is a marker of poor prognosis.
Bodoor K; Matalka I; Hayajneh R; Haddad Y; Gharaibeh W
Asian Pac J Cancer Prev; 2012; 13(7):3037-46. PubMed ID: 22994707
[TBL] [Abstract][Full Text] [Related]
45. Distinct IL-4-induced gene expression, proliferation, and intracellular signaling in germinal center B-cell-like and activated B-cell-like diffuse large-cell lymphomas.
Lu X; Nechushtan H; Ding F; Rosado MF; Singal R; Alizadeh AA; Lossos IS
Blood; 2005 Apr; 105(7):2924-32. PubMed ID: 15591113
[TBL] [Abstract][Full Text] [Related]
46. Incidence of diffuse large B-cell lymphoma of germinal center B-cell origin in whole diffuse large B-cell lymphoma: tissue fluorescence in situ hybridization using t(14;18) compared with immunohistochemistry.
Hirose Y; Masaki Y; Karasawa H; Shimoyama K; Fukushima T; Kawabata H; Ogawa N; Wano Y; Ozaki M
Int J Hematol; 2005 Jan; 81(1):48-57. PubMed ID: 15717689
[TBL] [Abstract][Full Text] [Related]
47. FOXP1 suppresses immune response signatures and MHC class II expression in activated B-cell-like diffuse large B-cell lymphomas.
Brown PJ; Wong KK; Felce SL; Lyne L; Spearman H; Soilleux EJ; Pedersen LM; Møller MB; Green TM; Gascoyne DM; Banham AH
Leukemia; 2016 Mar; 30(3):605-16. PubMed ID: 26500140
[TBL] [Abstract][Full Text] [Related]
48. Machine learning-based classification of diffuse large B-cell lymphoma patients by eight gene expression profiles.
Zhao S; Dong X; Shen W; Ye Z; Xiang R
Cancer Med; 2016 May; 5(5):837-52. PubMed ID: 26869285
[TBL] [Abstract][Full Text] [Related]
49. [Analysis of the feasibility and prognostic value of circulating tumor DNA monitoring in detecting gene mutations in patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy].
Zhou LH; Feng YQ; Hu YX; Huang H
Zhonghua Xue Ye Xue Za Zhi; 2023 Oct; 44(10):805-812. PubMed ID: 38049331
[No Abstract] [Full Text] [Related]
50. Large cleaved and immunoblastic lymphoma may represent two distinct clinicopathologic entities within the group of diffuse large B-cell lymphomas.
De Paepe P; Achten R; Verhoef G; Wlodarska I; Stul M; Vanhentenrijk V; Praet M; De Wolf-Peeters C
J Clin Oncol; 2005 Oct; 23(28):7060-8. PubMed ID: 16129841
[TBL] [Abstract][Full Text] [Related]
51. Identification of super enhancer-associated key genes for prognosis of germinal center B-cell type diffuse large B-cell lymphoma by integrated analysis.
Li X; Duan Y; Hao Y
BMC Med Genomics; 2021 Mar; 14(1):69. PubMed ID: 33663517
[TBL] [Abstract][Full Text] [Related]
52. Gene expression profiling of primary vitreoretinal lymphoma.
Arai A; Takase H; Yoshimori M; Yamamoto K; Mochizuki M; Miura O
Cancer Sci; 2020 Apr; 111(4):1417-1421. PubMed ID: 32056332
[TBL] [Abstract][Full Text] [Related]
53. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin.
Morin RD; Johnson NA; Severson TM; Mungall AJ; An J; Goya R; Paul JE; Boyle M; Woolcock BW; Kuchenbauer F; Yap D; Humphries RK; Griffith OL; Shah S; Zhu H; Kimbara M; Shashkin P; Charlot JF; Tcherpakov M; Corbett R; Tam A; Varhol R; Smailus D; Moksa M; Zhao Y; Delaney A; Qian H; Birol I; Schein J; Moore R; Holt R; Horsman DE; Connors JM; Jones S; Aparicio S; Hirst M; Gascoyne RD; Marra MA
Nat Genet; 2010 Feb; 42(2):181-5. PubMed ID: 20081860
[TBL] [Abstract][Full Text] [Related]
54. Molecular impact of selective NFKB1 and NFKB2 signaling on DLBCL phenotype.
Guo X; Koff JL; Moffitt AB; Cinar M; Ramachandiran S; Chen Z; Switchenko JM; Mosunjac M; Neill SG; Mann KP; Bagirov M; Du Y; Natkunam Y; Khoury HJ; Rossi MR; Harris W; Flowers CR; Lossos IS; Boise LH; Dave SS; Kowalski J; Bernal-Mizrachi L
Oncogene; 2017 Jul; 36(29):4224-4232. PubMed ID: 28368397
[TBL] [Abstract][Full Text] [Related]
55. Lack of a Prognostic Impact of the MyD88 L265P Mutation for Diffuse Large B Cell Lymphoma Patients Undergoing Autologous Stem Cell Transplantation.
Lee YS; Liu J; Fricano KA; Webb EM; Toolsie DR; Jones S; Rhoads JA; Vij R; Cashen AF; Abboud CN; Westervelt P; Bartlett NL; Dipersio JF; Kreisel FH; Lim KH
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2199-2204. PubMed ID: 28847710
[TBL] [Abstract][Full Text] [Related]
56. [Significance of microRNA-146b-5p in diffuse large B-cell lymphoma and its relationship with risk assessment].
Cao QW; Li HY; Yao XX; Wang JF
Zhonghua Xue Ye Xue Za Zhi; 2012 Dec; 33(12):1010-4. PubMed ID: 23363792
[TBL] [Abstract][Full Text] [Related]
57. EBV-positive HIV-associated diffuse large B cell lymphomas are characterized by JAK/STAT (STAT3) pathway mutations and unique clinicopathologic features.
Chapman JR; Bouska AC; Zhang W; Alderuccio JP; Lossos IS; Rimsza LM; Maguire A; Yi S; Chan WC; Vega F; Song JY
Br J Haematol; 2021 Sep; 194(5):870-878. PubMed ID: 34272731
[TBL] [Abstract][Full Text] [Related]
58. Association between BACH2 expression and clinical prognosis in diffuse large B-cell lymphoma.
Ichikawa S; Fukuhara N; Katsushima H; Takahashi T; Yamamoto J; Yokoyama H; Sasaki O; Fukuhara O; Nomura J; Ishizawa K; Ichinohasama R; Muto A; Igarashi K; Harigae H
Cancer Sci; 2014 Apr; 105(4):437-44. PubMed ID: 24450488
[TBL] [Abstract][Full Text] [Related]
59. [Immunohistochemical classification and prognosis of diffuse large B-cell lymphoma in China].
Chen Y; Xiao L; Zhu X; Lu C; Yu B; Fan D; Yin Y
Zhonghua Bing Li Xue Za Zhi; 2014 Jun; 43(6):383-8. PubMed ID: 25208988
[TBL] [Abstract][Full Text] [Related]
60. CD47 Expression Defines Efficacy of Rituximab with CHOP in Non-Germinal Center B-cell (Non-GCB) Diffuse Large B-cell Lymphoma Patients (DLBCL), but Not in GCB DLBCL.
Bouwstra R; He Y; de Boer J; Kooistra H; Cendrowicz E; Fehrmann RSN; Ammatuna E; Zu Eulenburg C; Nijland M; Huls G; Bremer E; van Meerten T
Cancer Immunol Res; 2019 Oct; 7(10):1663-1671. PubMed ID: 31409608
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
